Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May;53(5):1163-74.
doi: 10.1007/s10620-007-0018-8. Epub 2007 Oct 13.

Gastrointestinal manifestations of systemic sclerosis

Affiliations
Review

Gastrointestinal manifestations of systemic sclerosis

Robyn Domsic et al. Dig Dis Sci. 2008 May.

Abstract

Systemic sclerosis is a chronic disorder of connective tissue that affects the gastrointestinal tract in more than 80% of patients. Changes in neuromuscular function with progressive fibrosis of smooth muscle within the muscularis propria impair normal motor function, which may secondarily alter transit and nutrient absorption. Esophageal manifestations with gastroesophageal reflux and dysphagia are the most common visceral manifestation of the disease, often requiring more intense acid-suppressive medication. Gastric involvement may lead to gastroparesis, which can be found in up to 50% of patients. Severe small bowel disease can present as chronic intestinal pseudo-obstruction with distended loops of small intestine, bacterial overgrowth, impaired absorption and progressive development of nutritional deficiencies. While not studied as extensively, systemic sclerosis often also affects colorectal function resulting in constipation, diarrhea or fecal incontinence. Nutritional support and prokinetics have been used with some success to manage gastric and small or large bowel involvement in patients with systemic sclerosis. Despite advances in management, significant gastrointestinal manifestations of systemic sclerosis still carry a poor prognosis with a five-year mortality exceeding 50%.

PubMed Disclaimer

References

    1. Aliment Pharmacol Ther. 1992 Oct;6(5):565-77 - PubMed
    1. Scand J Gastroenterol. 1994 Sep;29(9):807-13 - PubMed
    1. Baillieres Best Pract Res Clin Rheumatol. 2000 Mar;14(1):17-35 - PubMed
    1. Dig Dis Sci. 2002 Apr;47(4):690-8 - PubMed
    1. J Rheumatol. 2001 Jul;28(7):1573-6 - PubMed

MeSH terms

LinkOut - more resources